232 related articles for article (PubMed ID: 36164414)
1. Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial.
Peng W; Jiang X; Zhu L; Li X; Zhou Q; Jie Y; You Z; Wu M; Jin X; Li X; Zhou S
Drug Des Devel Ther; 2022; 16():3183-3194. PubMed ID: 36164414
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A Multicenter Phase II Clinical Study.
Peng WY; Chen RX; Dai H; Zhu L; Li Y; Gao ZQ; Li XY; Zhou SY
Clin Ther; 2021 Mar; 43(3):613-628. PubMed ID: 33546885
[TBL] [Abstract][Full Text] [Related]
3. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
4. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.
Akpek EK; Wirta DL; Downing JE; Tauber J; Sheppard JD; Ciolino JB; Meides AS; Krösser S
JAMA Ophthalmol; 2023 May; 141(5):459-466. PubMed ID: 37022717
[TBL] [Abstract][Full Text] [Related]
6. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
7. Water-Free Cyclosporine Ophthalmic Solution vs Vehicle for Dry Eye Disease: A Randomized Clinical Trial.
Peng R; Jie Y; Long Q; Gong L; Zhu L; Zhong X; Zhao S; Yan X; Gu H; Wu H; Li G; Zhang K; Krösser S; Xu R; Hong J
JAMA Ophthalmol; 2024 Apr; 142(4):337-343. PubMed ID: 38451509
[TBL] [Abstract][Full Text] [Related]
8. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
[TBL] [Abstract][Full Text] [Related]
9. A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study.
Sheppard JD; Wirta DL; McLaurin E; Boehmer BE; Ciolino JB; Meides AS; Schlüter T; Ousler GW; Usner D; Krösser S
Cornea; 2021 Oct; 40(10):1290-1297. PubMed ID: 34481407
[TBL] [Abstract][Full Text] [Related]
10. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
Sall K; Stevenson OD; Mundorf TK; Reis BL
Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
Leonardi A; Van Setten G; Amrane M; Ismail D; Garrigue JS; Figueiredo FC; Baudouin C
Eur J Ophthalmol; 2016 Jun; 26(4):287-96. PubMed ID: 27055414
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study.
Chen D; Zhang S; Bian A; Hong J; Deng Y; Zhang M; Chen W; Shao Y; Zhao J
Medicine (Baltimore); 2019 Aug; 98(31):e16710. PubMed ID: 31374063
[TBL] [Abstract][Full Text] [Related]
13. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
Leonardi A; Messmer EM; Labetoulle M; Amrane M; Garrigue JS; Ismail D; Sainz-de-la-Maza M; Figueiredo FC; Baudouin C
Br J Ophthalmol; 2019 Jan; 103(1):125-131. PubMed ID: 29545413
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
[TBL] [Abstract][Full Text] [Related]
16. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
[TBL] [Abstract][Full Text] [Related]
17. TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China.
Dong Y; Wang S; Cong L; Zhang T; Cheng J; Yang N; Qu X; Li D; Zhou X; Wang H; Lee M; Wang M; Chen S; Ousler GW; Chen X; Xie L
Int Ophthalmol; 2022 Aug; 42(8):2459-2472. PubMed ID: 35192105
[TBL] [Abstract][Full Text] [Related]
18. Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial.
Tian L; Gao Z; Zhu L; Shi X; Zhao S; Gu H; Xu G; Wang L; Dai H; Zhang H; Jin X; Ma K; Xu Y; Ma L; Pei C; Ke B; Krösser S; Zhang Y; Jie Y
JAMA Ophthalmol; 2023 Apr; 141(4):385-392. PubMed ID: 36929413
[TBL] [Abstract][Full Text] [Related]
19. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.
Baudouin C; Figueiredo FC; Messmer EM; Ismail D; Amrane M; Garrigue JS; Bonini S; Leonardi A
Eur J Ophthalmol; 2017 Aug; 27(5):520-530. PubMed ID: 28362054
[TBL] [Abstract][Full Text] [Related]
20. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]